Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gold Sheet

Executive Summary

When Pfizer's Gerry Migliaccio told the recent PDA/FDA Pharmaceutical Supply Chain workshop that "Quality should not have to give the final approval of discontinuation" when a pharmaceutical company is considering dropping a substandard supplier, he was saying that other organizations, such as procurement or operations, should be willing to step up and make that decision themselves. Due to a transcription error in the June 2010 issue, this statement could be misconstrued to mean other organizations should be allowed to overrule the quality department

You may also be interested in...

FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality

A stronger pharma supply chain is in the works. Key is to put quality on CEO's radar screen. Progress made in supplier auditing, supply chain standard-setting and regulatory guidance development. Methods shared for improving supplier management. Supply chain mapping recommended. A better certificate of analysis. A think tank for signal detection. Improving distribution security and controls. Support for track-and-trace reimbursement incentive.

QUOTED. 25 January. 2021. Scott Whitaker.

US President Joe Biden has invoked the Defense Production Act to ramp up COVID-19 tests and personal protective equipment. See what AdvaMed’s CEO Scott Whitaker wrote in a letter to Biden where he asked that the device industry be included in the administration’s decision-making process.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts